Overview
HROW market data
Price History
HROW price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for HROW. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
BTIG Reiterates Buy on Harrow, Maintains $63 Price TargetBenzinga · Jul 21, 2026, 9:51 AM
Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To LucentisBenzinga · Jul 20, 2026, 12:04 PM
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingGlobenewswire Inc · Jul 20, 2026, 12:02 PM
Harrow Presents Three Studies Supporting IHEEZO, Low Viscosity Ocular Anesthetic Gel, And BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTIS At ASRS 2026 Annual MeetingBenzinga · Jul 20, 2026, 11:20 AM
Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung BioepisBenzinga · Jul 1, 2026, 11:10 AM
Harrow Adds Another Piece To Ophthalmology StrategyBenzinga · Jun 11, 2026, 3:42 PM
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareGlobenewswire Inc · Jun 10, 2026, 11:15 AM
8-K filing — HARROW, INC. (HROW)SEC EDGAR · Jun 3, 2026, 1:15 PM
Alpha Buying: When CEOs and CFOs Buy TogetherBenzinga · May 28, 2026, 4:20 PM
Harrow to Present at William Blair’s 46th Annual Growth Stock ConferenceGlobenewswire Inc · May 27, 2026, 11:15 AM